Date: 2012-08-21
Type of information: Company acquisition
Acquired company: RIEMSER Arzneimittel (Germany)
Acquiring company: AXA Private Equity (France)
Amount:
Terms: AXA Private Equity, the leading European diversified private equity firm, has acquired Riemser Arzneimittel AG, an international specialty pharmaceutical company, headquartered in Greifswald, Germany.
AXA Private Equity has acquired the shareholdings of Riemser’s founding Braun family and those of various minority stakeholders, including TVM Capital. The completion of the transaction remains subject to approval by the German competition authority.
Details: Riemser operates internationally and has a primary focus on the sales, marketing and lifecycle management of pharmaceutical products for niche therapeutic markets with high medical need in the fields of oncology, anti-infectives and dermatology. In 2011, Riemser, which has around 500 employees on its payroll, posted sales revenues of approximately €100 million and continues to grow profitably.
Related: pharmaceutical industry
oncology
infectious diseases
dermatology
